Key Highlights

  • A published screener snapshot of November 5, 2026 showed Progyny (NASDAQ:PGNY) at USD 34.20, up 13.62% on the latest session, 22.01% over one week and 32.25% over one month, a top Mid cap performer.
  • Longer windows are also strong: 33.80% over three months and 46.22% over six months, with the price one week earlier near USD 28.03 and one month earlier near USD 25.86 by simple arithmetic on the row.
  • Third quarter 2026 Revenue was USD 341.3 million, up 8.9% from USD 313.3 million, with Net Income of USD 26.3 million, adjusted EBITDA of USD 58.4 million at a 17.1% Margin and adjusted EPS of USD 0.52 against consensus of USD 0.31.
  • Full-year 2026 guidance is revenue of USD 1.365 billion to USD 1.385 billion, adjusted EBITDA of USD 235.0 million to USD 240.0 million and adjusted diluted EPS of USD 2.09 to USD 2.13.

What Moved Progyny (32.25% in One Month)

Progyny (NASDAQ:PGNY) reported third quarter 2026 results on November 4, 2026, and the shares gained 13.62% in the latest session of the snapshot. Revenue of USD 341.3 million compared with a published consensus of USD 340.76 million, and adjusted EPS of USD 0.52 compared with USD 0.31, a beat of USD 0.21 according to published coverage. GAAP EPS was USD 0.32. Net income was USD 26.3 million and adjusted EBITDA was USD 58.4 million. Average eligible members were about 7.176 million, up 6.2%. The company held USD 196 million in cash, cash equivalents and marketable securities, no debt, and an undrawn USD 200 million revolving Credit facility. Revenue growth of 8.9% compares with 6.2% member growth, which implies higher revenue per member.

Why a Stock Like This Re-Rates: Rationale

The identified catalyst is an Earnings beat, led by profit rather than revenue. Revenue was only USD 0.49 million above consensus (simple arithmetic), but adjusted EPS cleared by 68% (calculated). Buybacks add support: the company repurchased nearly 3 million shares for about USD 82.7 million in the quarter under its May 2026 program, with about 5.5 million shares bought in total and about USD 51 million remaining. Combined with the November 2025 program, 14.3 million shares have been repurchased. Fewer shares raise EPS for a given profit. The 46.22% six-month gain shows the rebound pre-dated the report, so a low-base recovery and sector rotation into healthcare services may also have contributed, which is general context.

Valuation, Liquidity and Risks After a Run

Published coverage lists a trailing P/E near 32.72, a forward P/E of 21.20 and a PEG Ratio of 2.01, with consensus EPS of USD 1.25 for the current year and USD 1.42 for next year. Trailing EPS was USD 0.92 on annual revenue of USD 1.29 billion. Revenue growth of 8.9% is modest after a 32.25% monthly gain, and valuation now prices in continued execution. Employer benefit contracts renew annually and member utilization can shift costs. Progyny (NASDAQ:PGNY) sits in the mid cap bucket of USD 2 billion to USD 10 billion, a small number of trades can move the price, spreads can be wide, and the move may reverse. The 52-week range and average Volume could not be confirmed here.

Where Things Stand

Progyny (NASDAQ:PGNY) surged 32.25% in a month largely because a third quarter profit beat, adjusted EPS of USD 0.52 against USD 0.31, and active buybacks followed a 33.80% three-month rally. In a published screener snapshot of November 5, 2026 it ranks among the top mid caps over one week, at 22.01%, and one month. At USD 34.20 it is 46.22% higher over six months. Past gains do not predict future moves.